De Gaulle Fleurance & Associés advises Lysogene for its funding by the BPI
Biotech
Paris, December 2nd ,2021
The biopharmaceutical company, Lysogene, has obtained a €4.3 million non-dilutive funding from Bpifrance to support its development.
This funding is composed ...